Welcome to our dedicated page for Bionoid Pharma news (Ticker: BINP), a resource for investors and traders seeking the latest updates and insights on Bionoid Pharma stock.
Bionoid Pharma Inc (BINP) combines artificial intelligence with healthcare innovation to drive digital transformation in the pharmaceutical sector. This page serves as the definitive source for all company announcements, offering stakeholders timely access to press releases, financial updates, and strategic developments.
Investors and industry professionals will find curated updates on AI integration milestones, acquisition strategies, and operational advancements. The resource prioritizes accuracy and relevance, covering earnings reports, partnership announcements, and technology deployments without speculative commentary.
Content is organized to provide clear insights into BINP’s progress in merging healthcare expertise with AI-driven solutions. Regular updates ensure visitors stay informed about initiatives impacting customer engagement models and market positioning.
Bookmark this page for streamlined access to Bionoid Pharma’s evolving narrative in the digital health landscape. Verify facts directly through primary filings and official statements linked within each update.
Bionoid Pharma (OTC PINK:BINP) has announced the completion of its audited financial statements for fiscal year 2024. The audit was performed by Aloba Awomolo & Partners LLP, Chartered Professional Accountants. CEO Wayne Cockburn highlighted this as a significant milestone for the company, positioning them for their next phase of corporate growth strategy.
The company plans to use this audit completion as a stepping stone toward their application to uplist to a more senior stock exchange. The audited financial statements will be made available on the OTC Markets website, demonstrating the company's commitment to transparency and corporate governance.
Bionoid Pharma (OTC PINK:BINP) has appointed Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year 2024. This strategic move follows the company's recent application to uplist to the OTCQB Venture Market.
The engagement of the new auditor demonstrates Bionoid's focus on enhancing financial governance and transparency, aimed at providing investors with improved visibility and liquidity. The audit is positioned as a important step in the company's strategy to achieve a more senior market listing.
Bionoid Pharma (OTC PINK:BINP) has submitted an application to uplist from OTC Pink to the OTCQB Venture Market. The process involves OTC Markets Group reviewing the company's financials, governance, and disclosures.
Upon approval, Bionoid will be able to utilize the SEC's modernized Rule 15c2-11 framework, enabling enhanced market maker participation through the IDQS system without the traditional 30-day waiting period. CEO Wayne Cockburn stated this move aims to enhance trading efficiency, liquidity, and price discovery, benefiting both institutional and retail investors.
The uplisting remains subject to final approval, with the company committed to providing updates throughout the process.
Bionoid Pharma (OTC PINK:BINP) has announced the completion of its financial audits for fiscal years 2022 and 2023 by PCAOB-registered firm Olayinka Oyebola & Co. This development represents a key milestone in the company's commitment to financial transparency and regulatory compliance.
The audits were conducted according to Public Company Accounting Oversight Board (PCAOB) standards, ensuring the accuracy of Bionoid's financial reporting. The firm is also on schedule to complete the company's 2024 financial statements.
CEO Wayne Cockburn emphasized that this achievement aligns with Bionoid's expansion strategy, which focuses on strategic acquisitions and AI-driven growth initiatives. The company is particularly targeting revenue-generating e-commerce acquisitions and continues to integrate its AI Maverick platform for sustainable growth.
Bionoid Pharma (OTC PINK:BINP) has outlined its corporate growth strategy for 2025, focusing on two main pillars: acquiring revenue-positive e-commerce websites in the health and wellness sector and implementing its proprietary AI Maverick Intel platform. The AI-driven marketing system aims to enhance customer engagement, optimize advertising efficiency, and deliver tailored user experiences.
CEO Wayne Cockburn emphasized the company's vision of scaling operations through strategic acquisitions while leveraging AI technology. The company plans to expand its portfolio with high-value, revenue-generating e-commerce websites in the health and wellness sector, with each acquisition aligned to support long-term objectives.
Bionoid Pharma (OTC PINK:BINP) has generated over $100,000 in revenue following a Binding Letter of Intent (LOI) with Your Supplement Supply Store The agreement marks the company's expansion into the health and wellness e-commerce sector.
Under the LOI terms, Bionoid retains all revenue generated during the transition period before finalizing the Asset Purchase Agreement (APA). The company's strategy involves acquiring e-commerce platforms and implementing its proprietary AI Maverick technology to enhance customer engagement and operational efficiency.
Bionoid Pharma (OTC PINK:BINP) has signed a Binding Letter of Intent (LOI) to acquire PrimeEnduro.com, an e-commerce platform, from Vitawin Supplements The acquisition will be structured as an Asset Purchase Agreement (APA), with Bionoid retaining all revenue generated by PrimeEnduro.com prior to the APA finalization. The company plans to integrate its AI Maverick technology into the platform to provide personalized health assistants and enhance the shopping experience. This strategic move aims to expand Bionoid's presence in the health and wellness sector through an AI-enhanced e-commerce ecosystem.
Bionoid Pharma (OTC PINK:BINP) has introduced AI Maverick, a new sales automation platform, through the BizUnLearned Podcast. The platform aims to revolutionize traditional sales processes by replacing repetitive tasks with AI-powered automation. AI Maverick features include two-way communication, real-time buyer intent response, and scalable operations handling from 10 to 100,000 interactions. The system focuses on addressing common sales challenges like high SDR turnover and inconsistent messaging while providing seamless data management and 24/7 engagement capabilities.
Bionoid Pharma (BINP) announces the upcoming launch of AI Maverick 2.0, an AI-powered sales automation platform designed to replace traditional Sales Development Representatives (SDRs). The platform features two-way communication technology that autonomously manages the entire sales pipeline, from initial outreach to final conversion. Key benefits include increased productivity through automation, consistent engagement across channels, cost savings by reducing SDR teams, and seamless scalability. The technology aims to address common challenges in sales teams such as high turnover, workload management, and communication inefficiencies.
Bionoid Pharma (OTC PINK:BINP) has announced the incorporation of its wholly owned subsidiary, Enhanced Supplements , marking a strategic move into e-commerce. The subsidiary will focus on serving the bodybuilding and resistance training market with high-quality supplements, offering wholesale pricing options for bulk buyers. The platform will integrate BINP's proprietary AI Maverick technology for marketing optimization, providing personalized recommendations and targeted advertising to enhance customer experience and reach.
